

**Supplementary table 2:** IOIbs associated factors: Bivariate analysis

	Total ADRs		
	HR	95%CI	p
Age, years	1.02	1.01-1.05	0.04
Sex, male	2.21	1.05-4.62	0.03
Disease duration, years	1.03	0.98-1.08	0.21
Married	1.10	0.50-2.42	0.80
No studies or primary school	1.26	0.58-2.70	0.54
Tobacco	0.92	0.32-2.57	0.87
Five-year period:			
2007-2012	1	-	-
2002-2003	0.45	0.15-1.34	0.15
Positive ACPA	1.001	0.99-1.01	0.49
Positive RF	1.75	0.72-4.22	0.21
Hemoglobine	0.91	0.66-1.25	0.57
Baseline DAS > 5.1	0.97	1.40-2.74	0.87
ESR	1.003	0.99-1.01	0.53
Baseline HAQ >1.5	1.04	0.69-1.57	0.82
Lymphocyte count ≤1500cells/mm <sup>3</sup>	0.99	0.99-0.99	0.03
Baseline Comorbid conditions			
Hypertension	1.51	0.22-10.14	0.66
Hypercholesterolemia	1.71	0.26-11.87	0.55
Congestive heart failure	1.71	0.26-11.12	0.57
Diabetes Mellitus	1.53	0.23-9.97	0.65
Cancer	1.73	0.26-11.24	0.56
Depression	1.70	0.26-11.01	0.57
Renal failure	1.75	0.27-11.33	0.55
Osteoporosis	1.19	0.17-7.97	0.85
COPD	1.52	0.7-3.5	0.26
Liver disease	1.52	0.23-9.78	0.65
Corticosteroids	2.26	1.34-2.82	0.002
Concomitant DMARDs	1.01	0.66-1.56	0.93
No anti-TNF	1.78	0.83-3.81	0.13

<b>Biologic Agents:</b>			
<b>Etanercept/Golimumab</b>	1	-	-
<b>Adalimumab</b>	1.31	0.52-3.24	0.55
<b>Infliximab</b>	1.71	0.43-6.69	0.43
<b>Certolizumab</b>	2.38	0.65-8.71	0.18
<b>Rituximab</b>	2.96	1.14-7.68	0.026
<b>Tocilizumab</b>	0.98	0.12-7.55	0.98
<b>Abatacept</b>	1.74	0.35-8.57	0.49

HR=hazard ratio, CI=confidence interval.